posted
Does anyone know why this is moving? This is the latest PR I have seen.
Board to Facilitate R & D Efforts Leading to Company's FDA Application for its Single-Use Skin Cancer Treatment Carcinoderm LOS ANGELES, Nov. 3, 2004 (PRIMEZONE) -- Bio-Life Labs, Inc. (OTCBB:BLFE) today announced the formation of its Medical Advisory Board and the appointment of Karen F. Han, M.D., Ph.D. as one of the initial members. Based at the Palo Alto Medical Foundation as a certified clinical dermatologist, Dr. Han will serve as a Bio-Life Medical Advisory Board member and participate in the Company's Internal Review Board.
Dr. Han, who first learned about and approached Bio-Life in preparation for an August speech at the 56th Annual Meeting of the Pacific Dermatologic Association, has expressed initial optimism regarding the Company's first product Carcinoderm(tm), a topical treatment that is formulated to destroy skin cancer cells in a one-time application without harming surrounding healthy tissue.
"We are thrilled that Dr. Han has become a member of our Medical Advisory Board, and will participate in our effort to bring Carcinoderm through the FDA approval process and beyond," stated the Company's Executive Vice President and Chief Medical Officer David Karam, M.D., Ph.D. "Dr. Han's professional standing as a dermatologist at the Palo Alto Medical Foundation is enhanced by her commitment to combat such skin cancers, and our work to bring Carcinoderm to market can only benefit from her participation."
Dr. Han, who practices at Palo Alto Medical Clinic in Palo Alto, California, as well as Redwood Shores Health Center in Redwood City, earned her degree at Northwestern University Medical School. She completed her internship at Kaiser Permanente Santa Clara Medical Center and her residency at UCLA. Her professional affiliations include the American Society for Dermatologic Surgery and American Academy of Dermatology.
About Bio-Life Labs
Bio-Life, Labs, Inc. is a research-driven biotechnology company focused on discovery, development, manufacturing, and commercialization of breakthrough treatments for cancer, diabetes mellitus, and hepatitis C. The Company's first product candidate Carcinoderm(tm) is a topical treatment that in the estimation of Management destroys skin cancer cells in patients diagnosed with basal cell carcinoma, squamous cell carcinoma, and malignant melanoma in a one-time application without harming surrounding healthy tissue. Carcinoderm(tm) is currently being studied in what the Company believes are FDA-conforming clinical trials with patients who have biopsy-confirmed cases of all three types of skin cancer.
Bio-Life Labs' corporate headquarters is located in Los Angeles, California; its research and development facility is located in the El Paso, Texas area.
Bio-Life Labs cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Bio-Life Labs that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Bio-Life Labs' business including, without limitation, statements about: the potential for its product candidates to result in marketable products; difficulties or delays in research, development, testing, obtaining regulatory approval, producing and marketing its technologies and product candidates; unexpected adverse side effects or inadequate therapeutic efficacy of its product candidates that could delay or prevent product development or commercialization, or that could result in recalls or product liability claims; the scope and validity of patent protection for its product candidates; its ability to meet product candidate development objectives; competition from other pharmaceutical or biotechnology companies; its ability to obtain additional financing to support its operations; its ability to attract and retain experienced scientists and management; and other risks detailed in Bio-Life Labs' Securities and Exchange Commission filings. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Bio-Life Labs undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.
CONTACT: Bio-Life Labs, Inc. Corporate Communications (310) 943-6445
on this stock.
-------------------- Pennies are for trading. Posts: 82 | From: dixon ca us | Registered: Jun 2004
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
